Sengupta Nishan, Nichol Michael B, Wu Joanne, Globe Denise
Center for Pharmaceutical Appraisal and Outcomes Research, Abbott Lab, Lake Bluff, Illinois, USA.
Med Care. 2004 Sep;42(9):927-37. doi: 10.1097/01.mlr.0000135812.52570.42.
Transforming generic health-related quality of life (HRQOL) instruments to a summary utility index is useful for deriving quality-adjusted life years (QALY) in any cost/QALY analysis.
The purpose of this study was to investigate the role of the SF-12 in predicting utility scores derived from Health Utility Index (HUI3) and Visual Analog Scale (VAS).
Data were obtained from a survey of 6923 managed care patients in the United States, aged 18 to 93 years, selected by strata of medication usage (at least 1 medication in target year, 5 or more medications, target medications, and both). The SF-12 was used to assess self-reported HRQOL. Utility was measured by the HUI3 and a VAS. The SF-12 items were used to predict HUI3 and VAS scores using ordinary least square regressions, with sociodemographic covariates. A second model entered each SF-12 item as categorized responses. A third model used the Physical Composite and Mental Composite scores to predict HUI3 and VAS scores.
The SF-12 items and sociodemographic covariates accounted for 35% to 55% of the variations in HUI3 and VAS scores, respectively. Age and most SF-12 items were significantly (P < 0.0001) associated with both utility scores in all 3 models.
This research provides support that an algorithm can be derived from the SF-12 to estimate utility scores based on the HUI3 and VAS for studies in populations where utility has not or cannot be measured directly.
将通用的健康相关生活质量(HRQOL)工具转化为综合效用指数,对于在任何成本/质量调整生命年(QALY)分析中得出QALY很有用。
本研究的目的是调查SF-12在预测从健康效用指数(HUI3)和视觉模拟量表(VAS)得出的效用分数方面的作用。
数据来自对美国6923名管理式医疗患者的调查,年龄在18至93岁之间,按用药情况分层选取(目标年份至少使用1种药物、5种或更多药物、目标药物以及两者都用)。SF-12用于评估自我报告的HRQOL。效用通过HUI3和VAS进行测量。使用普通最小二乘法回归,并纳入社会人口统计学协变量,用SF-12项目预测HUI3和VAS分数。第二个模型将每个SF-12项目作为分类反应纳入。第三个模型使用身体综合得分和心理综合得分来预测HUI3和VAS分数。
SF-12项目和社会人口统计学协变量分别解释了HUI3和VAS分数中35%至55%的变异。在所有3个模型中,年龄和大多数SF-12项目与两种效用分数均显著相关(P < 0.0001)。
本研究支持可以从SF-12推导出一种算法,用于在效用未直接测量或无法直接测量的人群研究中,基于HUI3和VAS估计效用分数。